TARGET AUDIENCE

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer (BC).

OVERVIEW OF ACTIVITY
Breast cancer remains the most frequently diagnosed cancer in women, and in 2017 in the United States alone the disease will culminate in an estimated 255,180 new cases and 41,070 deaths. Current clinical management is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these approaches. Although the diagnosis and treatment of BC remains, in many ways, more advanced than that of other solid tumors, challenging issues in basic management continue to require refinement. Increasingly, an emphasis is being placed on a “personalized medicine” approach that promises to more effectively identify specific treatments that will benefit individuals based on specific patient- and disease-related characteristics. The pace of change in the field of breast medical oncology has been rapid, and it is expected that a plethora of new data will continuously be disseminated and will require ongoing efforts to keep medical professionals informed about the unique mechanisms of action, toxicities and effectiveness of novel agents.

Although medical oncologists have been routinely responsible for counseling patients with regard to therapeutic decision-making, oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and in the preservation of patient physical and psychosocial well-being. These video proceedings from the third part of a 7-part integrated CNE curriculum originally held at the 2017 ONS Annual Congress feature discussions with leading BC investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

LEARNING OBJECTIVES

• Apply existing and emerging research data to the diagnostic, therapeutic and supportive care of patients with early and advanced BC.
• Describe the influence of tumor phenotypes and/or molecular profiling assays in tailoring systemic treatment decisions for patients with early and advanced BC.
• Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of BC, including endocrine agents, chemotherapy regimens and biologic treatments.
• Develop a plan to manage the side effects associated with commonly employed systemic therapies to support quality of life and continuation of treatment.
• Assess emerging research on the safety and efficacy of novel agents under development in preparation for the potential availability of these therapies.
• Recall ongoing trials of other investigational approaches and agents in BC, and refer patients and obtain consent for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
CNE credit is no longer available for this issue

ONCC/ILNA CERTIFICATION INFORMATION
CNE credit is no longer available for this issue

FOR SUCCESSFUL COMPLETION
This is a video CNE program.
CNE credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Emily Olson, APRN, CNP, MSN
Instructor in Oncology
Mayo Clinic, Rochester
Division of Medical Oncology
Rochester, Minnesota

Advisory Committee: AstraZeneca Pharmaceuticals LP.

Elizabeth A O’Reilly, RN, NP, MSN, MPH
Nurse Practitioner
Breast Oncology
Susan F Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts

No relevant conflicts of interest to disclose.

Joyce O’Shaughnessy, MD
Chair, Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas

Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology; Contracted Research: Merck.

Denise A Yardley, MD
Senior Investigator, Breast Cancer Research
Sarah Cannon Research Institute 
Tennessee Oncology PLLC
Nashville, Tennessee 

Advisory Committee: Novartis; Speakers Bureau: Eisai Inc, Genentech BioOncology.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech BioOncology, Lilly, Novartis and Puma Biotechnology Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: July 2017
Expiration date: July 2018

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.